ANI Pharmaceuticals, Inc.
ANIP
$63.26
$1.863.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.20% | 23.60% | 34.27% | 44.26% | 53.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.20% | 23.60% | 34.27% | 44.26% | 53.87% |
| Cost of Revenue | 37.85% | 35.84% | 39.65% | 36.64% | 31.74% |
| Gross Profit | 19.28% | 16.54% | 31.09% | 49.21% | 70.94% |
| SG&A Expenses | 46.72% | 50.46% | 42.46% | 41.67% | 41.04% |
| Depreciation & Amortization | 13.28% | 2.11% | 3.00% | 4.66% | 4.95% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.15% | 35.39% | 35.40% | 35.29% | 31.82% |
| Operating Income | -70.49% | -60.53% | 23.75% | 248.47% | 423.00% |
| Income Before Tax | -211.78% | -156.85% | 437.00% | 224.39% | 131.71% |
| Income Tax Expenses | -437.60% | -123.91% | 257.91% | 190.56% | 107.40% |
| Earnings from Continuing Operations | -198.63% | -152.99% | 623.65% | 235.02% | 139.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.63% | -152.99% | 623.65% | 235.02% | 139.21% |
| EBIT | -70.49% | -60.53% | 23.75% | 248.47% | 423.00% |
| EBITDA | -24.67% | -28.83% | 8.77% | 50.05% | 146.67% |
| EPS Basic | -220.85% | -183.30% | 365.54% | 194.52% | 127.77% |
| Normalized Basic EPS | -128.27% | -93.67% | 107.59% | 323.99% | 149.73% |
| EPS Diluted | -224.65% | -189.91% | 353.94% | 192.64% | 127.28% |
| Normalized Diluted EPS | -129.31% | -94.29% | 106.82% | 320.32% | 149.20% |
| Average Basic Shares Outstanding | 7.37% | 10.88% | 14.39% | 14.37% | 10.65% |
| Average Diluted Shares Outstanding | 6.69% | 10.78% | 15.03% | 15.57% | 11.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.01% | -2.89% | 1.19% | 1.74% | 3.55% |
